STOCK TITAN

Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

PTGX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
12 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+8% close of June 9, 2026
1-year change
+57.3% closing prices, November 13, 2025 to November 13, 2026
1-month change
-5.4% closing prices, October 13, 2026 to November 13, 2026

Company Description

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a discovery-through-late-stage development biopharmaceutical company in the pharmaceutical preparation manufacturing industry. According to company disclosures, its work centers on a proprietary discovery platform for constrained peptide-based drug candidates, with multiple investigational therapies advancing through Phase 3 clinical development and a broader preclinical pipeline.

Business focus and therapeutic areas

Protagonist describes itself as a biopharmaceutical company spanning discovery to late-stage development. Two novel peptides derived from its proprietary discovery platform are in advanced Phase 3 development: icotrokinra (formerly JNJ-2113) and rusfertide. These programs, together with additional preclinical candidates, position the company in inflammatory and immunological diseases and hematology.

Icotrokinra is characterized by the company as a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin‑23 receptor (IL‑23R). It was jointly discovered by scientists at Protagonist and Johnson & Johnson under an IL‑23R collaboration. Protagonist reports that it was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Icotrokinra is licensed to Janssen Biotech, Inc. (also referenced as J&J Innovative Medicines or Johnson & Johnson), and a New Drug Application (NDA) for icotrokinra has been submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate to severe plaque psoriasis. The company also notes an application to the European Medicines Agency for this indication.

Beyond plaque psoriasis, Protagonist highlights that icotrokinra is being studied in a broad clinical development program, including:

  • Phase 3 ICONIC studies in moderate-to-severe plaque psoriasis, including ICONIC‑LEAD and ICONIC‑TOTAL.
  • Phase 3 and Phase 2b/3 studies in active psoriatic arthritis (ICONIC‑PsA 1 and ICONIC‑PsA 2).
  • The Phase 2b ANTHEM‑UC study in moderately to severely active ulcerative colitis, with data supporting Phase 3 development in ulcerative colitis and a Phase 2b/3 program in Crohn’s disease.

Rusfertide is described as a mimetic of the natural hormone hepcidin and a first‑in‑class investigational subcutaneous hepcidin mimetic peptide. It is designed to regulate iron homeostasis and red blood cell production, with the goal of controlling hematocrit levels in adults with polycythemia vera (PV), a rare blood disorder characterized by erythrocytosis. Protagonist and its partner Takeda report that rusfertide is being evaluated in the Phase 3 VERIFY study and related extension studies (including THRIVE), and that rusfertide has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the U.S. FDA for PV. An NDA for rusfertide for the treatment of adults with polycythemia vera has been submitted to the FDA.

Collaboration and licensing model

Protagonist’s disclosures emphasize a collaboration-driven model for its late-stage assets. Icotrokinra is licensed to Janssen Biotech, Inc., a Johnson & Johnson company, under a license and collaboration agreement that covers discovery and development of IL‑23R‑targeted compounds. Under this collaboration, Protagonist led early-stage development and Johnson & Johnson is responsible for later-stage clinical development and commercialization rights.

For rusfertide, Protagonist has entered into a worldwide collaboration and license agreement with Takeda Pharmaceuticals. The company states that rusfertide is being co-developed and will be co-commercialized with Takeda, with Protagonist remaining primarily responsible for development through NDA filing. The agreement includes provisions for milestone payments, opt-out rights, and tiered royalties on worldwide net sales, as described in company news releases.

Pipeline beyond lead programs

In addition to icotrokinra and rusfertide, Protagonist reports several preclinical and early clinical programs derived from its peptide discovery platform. These include:

  • PN‑881, described as a first‑in‑class oral IL‑17 peptide antagonist. Company announcements note preclinical proof‑of‑concept data and initiation of a Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults.
  • PN‑477, referred to as an obesity triple agonist peptide, with oral (PN‑477o) and subcutaneous (PN‑477sc) formulations progressing through IND‑enabling studies.
  • An oral hepcidin program, from which Protagonist plans to nominate a development candidate for IND‑enabling studies.

Across these programs, Protagonist characterizes its focus as addressing clinically and commercially validated targets with peptide-based therapeutics, particularly in inflammatory and immunological (I&I) indications and hematologic disorders.

Regulatory and clinical milestones

Company news releases highlight several regulatory milestones and clinical data readouts relevant to PTGX:

  • Submission of an NDA to the U.S. FDA for icotrokinra in moderate to severe plaque psoriasis, and a corresponding application to the EMA.
  • Positive Phase 3 data for icotrokinra in plaque psoriasis from ICONIC‑LEAD, ICONIC‑TOTAL, and ICONIC‑ADVANCE 1 and 2, including comparisons to placebo and to deucravacitinib.
  • Phase 2b ANTHEM‑UC data in ulcerative colitis, with icotrokinra meeting the primary endpoint of clinical response at multiple doses and supporting further development in UC and Crohn’s disease.
  • Phase 3 VERIFY data for rusfertide in polycythemia vera, including 32‑week and 52‑week analyses showing response rates defined by absence of phlebotomy eligibility, hematocrit control, and patient‑reported outcomes, as reported by Protagonist and Takeda.
  • Long‑term extension data from THRIVE and combined REVIVE/THRIVE analyses, indicating reductions in phlebotomy rates and sustained hematocrit control in patients treated with rusfertide.

These milestones are presented by the company as part of a progression from discovery through late-stage development, with multiple programs at or approaching regulatory review.

Corporate profile and listing

Protagonist Therapeutics, Inc. is incorporated in Delaware and lists its principal executive offices in Newark, California, as disclosed in its Form 8‑K filings. The company’s common stock trades on the Nasdaq Global Market under the ticker symbol PTGX. SEC filings reference Protagonist as a biopharmaceutical company and include regular updates on financial results, corporate presentations, and stockholder meeting outcomes.

Through its SEC reports and press releases, Protagonist emphasizes its role as a clinical‑stage biopharmaceutical company advancing peptide‑based therapies from discovery into late-stage development, with a strategy that combines internal R&D with collaborations with larger pharmaceutical partners.

How investors may view PTGX

From the information Protagonist provides, PTGX represents exposure to a pipeline of peptide therapeutics targeting validated pathways such as IL‑23, IL‑17, and hepcidin. The company’s narrative focuses on:

  • Late-stage assets (icotrokinra and rusfertide) with NDAs submitted or planned.
  • Partnerships with Johnson & Johnson and Takeda for development and commercialization.
  • Expansion of its platform into additional inflammatory, immunological, and metabolic indications via PN‑881, PN‑477, and oral hepcidin programs.

All of these elements are drawn from Protagonist’s own descriptions in press releases and SEC filings, and reflect how the company characterizes its business and pipeline to the market.

Stock Performance

$130.95
-2.55%
-3.43
Last updated: November 13, 2026 at 16:00
+57.3%
Performance 1 year

Protagonist Therapeutics (PTGX) closed at $130.95 on November 13, 2026. Over the past 12 months, the price has gained 57.3%.

See what a $1,000 investment in PTGX would be worth today

Average down calculator for PTGX

PTGX Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
183,629
Shares Sold
5
Transactions
Most Recent Transaction
Ali Asif (Chief Financial Officer) sold 58,629 shares at an average of $141.78 on September 30, 2026

Insider selling at Protagonist Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Protagonist Therapeutics generated $46.0M in revenue in FY2025, operating income reached -$158.1M, and net income was -$130.1M. Diluted earnings per share stood at -$2.05. The company generated $57.7M in operating cash flow. The current ratio was 12.71, measuring current assets divided by current liabilities.

$46.0M
Revenue (FY2025)
-$130.1M
Net Income (FY2025)
$57.7M
Operating Cash Flow

Upcoming Events

NOV
16
November 16, 2026 Marketing

UBS presentation London

Protagonist management in London for UBS on Nov 16: individual meetings plus a fireside chat; investor engagement in EMEA.
NOV
17
November 17, 2026 Marketing

Jefferies presentation London

Protagonist management in London for Jefferies on Nov 17: individual meetings and a fireside chat; investor meetings and outreach.
Q1
2027
Q1 2027 Clinical

PN-881 Phase 2b start

Planned start of PN-881 Phase 2b psoriasis trial in early Q1 2027; multicenter sites and enrollment details to be announced.
YEAR
2027
2027 Clinical

Other clinical starts

Company expects three additional clinical study starts during 2027, timing unspecified; may drive pipeline progress and milestones.
JUN
30
June 30, 2027 - June 30, 2030 Corporate

Options vesting schedule

8,650 options granted 2026-06-30; vest 25% on 2027-06-30 then monthly through 2030-06-30; $122.58 exercise.
JUN
30
June 30, 2027 - June 30, 2030 Corporate

RSUs vesting schedule

2,275 RSUs granted 2026-06-30; vest in four equal annual installments from 2027-06-30 through 2030-06-30.
JUL
15
July 15, 2027 - July 15, 2030 Corporate

Employee awards vesting

12,600 options and 3,330 RSUs granted 2026-07-15; 25% cliff on 2027-07-15, then monthly/annual vesting through 2030-07-15.
APR
15
April 15, 2030 Corporate

Awards fully vest

Final vesting completes four years after 2026-04-15 for 55,425 options and 14,425 RSUs; potential dilution.

Protagonist Therapeutics has 8 upcoming scheduled events. The next event, "UBS presentation London", is scheduled for November 16, 2026 (tomorrow). Investors can track these dates to stay informed about potential catalysts that may affect the PTGX stock price.

Short Interest History

Last 12 Months

Short interest in Protagonist Therapeutics (PTGX) currently stands at 10.2 million shares, down 0.5% from the previous reporting period, representing 16.1% of the float. Since November 2025, short interest has increased by 74.1%.

Days to Cover History

Last 12 Months

Days to cover for Protagonist Therapeutics (PTGX) currently stands at 16.9 days, up 40.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 138.9%. Across the settlements charted above, it has ranged from 6.0 to 16.9 days.

PTGX Company Profile & Sector Positioning

Protagonist Therapeutics (PTGX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing PTGX often look at related companies in the same sector, including Praxis Precision Medicines, Inc. (PRAX), Rhythm Pharmaceuticals, Inc. (RYTM), Corcept Therapeutics Inc. (CORT), Abivax SA (ABVX), and Spyre Therapeutics, Inc. (SYRE). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PTGX's relative position within its industry.

Frequently Asked Questions

The current stock price of Protagonist Therapeutics (PTGX) is $130.95 as of November 13, 2026.

The market cap of Protagonist Therapeutics (PTGX) is approximately $8.5B. Learn more about what market capitalization means .

The FY2025 revenue of Protagonist Therapeutics (PTGX) is $46.0M, from its most recent completed fiscal year.

The FY2025 net income of Protagonist Therapeutics (PTGX) is -$130.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Protagonist Therapeutics (PTGX) is -$2.05 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Protagonist Therapeutics (PTGX) is $57.7M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Protagonist Therapeutics (PTGX), current assets divided by current liabilities, was 12.71 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Protagonist Therapeutics (PTGX) is -$158.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

Protagonist Therapeutics, Inc. is a discovery-through-late-stage development biopharmaceutical company that uses a proprietary discovery platform to develop constrained peptide-based drug candidates. Its lead investigational therapies include icotrokinra, a targeted oral peptide that selectively blocks the IL-23 receptor, and rusfertide, a hepcidin mimetic being developed for polycythemia vera.

The company highlights two novel peptides in advanced Phase 3 development: icotrokinra (formerly JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor, and rusfertide, a first-in-class investigational subcutaneous hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production in polycythemia vera.

Icotrokinra was jointly discovered by Protagonist and Johnson & Johnson scientists under an IL-23R collaboration. Protagonist reports that it led development through Phase 1, after which Johnson & Johnson assumed responsibility for Phase 2 and later stages. Icotrokinra is licensed to Janssen Biotech, Inc., a Johnson & Johnson company, which holds exclusive worldwide rights to develop and commercialize it under the collaboration agreement.

Rusfertide is being developed for the treatment of adults with polycythemia vera, a rare blood disorder characterized by overproduction of red blood cells. It is a hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to help control hematocrit levels in these patients.

Protagonist has a license and collaboration agreement with Janssen Biotech, Inc., a Johnson & Johnson company, covering icotrokinra and related IL-23R-targeted compounds. It also has a worldwide collaboration and license agreement with Takeda Pharmaceuticals for rusfertide, under which rusfertide is being co-developed and will be co-commercialized, with Protagonist primarily responsible for development through NDA filing.

In company communications, Protagonist describes several preclinical and early clinical programs, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477 (with oral and subcutaneous forms), and an oral hepcidin program. These programs are positioned as targeting clinically and commercially validated pathways in inflammatory, immunological, and metabolic diseases.

Yes. Protagonist reports that an NDA for icotrokinra for adults and adolescents with moderate to severe plaque psoriasis has been submitted to the U.S. FDA, with a corresponding application to the European Medicines Agency. Together with Takeda, the company has also announced submission of an NDA to the FDA for rusfertide for the treatment of adults with polycythemia vera.

According to company press releases and SEC filings, Protagonist Therapeutics’ common stock trades on Nasdaq under the ticker symbol PTGX.

Protagonist and its partner describe icotrokinra as being evaluated in a broad clinical program that includes moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active ulcerative colitis, and a Phase 2b/3 program in Crohn’s disease, reflecting its mechanism as a targeted oral peptide that selectively blocks the IL-23 receptor.

Protagonist characterizes its strategy as advancing peptide-based therapeutics from discovery through late-stage development, focusing on clinically and commercially validated targets such as IL-23, IL-17, and hepcidin. The company combines internal discovery and early development with collaborations for later-stage development and commercialization.